Читать книгу Biologics, Biosimilars, and Biobetters - Группа авторов - Страница 85

Rituxan^® (rituximab) was developed by IDEC Pharmaceuticals under the name IDEC‐C2B8. Rituxan^® is currently co‐marketed in the United States by Biogen Idec and Roche subsidiary Genentech.

Indication: Non‐Hodgkin's lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis

Manufacturer: Roche

Global Sales in 2017: $9.2 billion

Generic name: Rituximab

Launch date: 1997